Stock Analysis of Acorda Therapeutics Inc (ACOR) - Birds Eye View

1W   2W   1M   3M   1Y   2Y   5Y   
Overview
Code ACOR
Close 0.661
Change -0.219 / 24.86 %
Volume 399589
Vol Change 57647.00 / 16.86 %
IndustryDrug Manufacturers-Specialty & Generic
SectorHealthcare
AIO Strength Index
Technical StrengthStrong Bearish
Growth Index Poor Growth Stock
Value Index Low Value Stock
Profitability Index Poor Profitability Stock
Stability Index Poor Stability Stock


Fundamental View of Acorda Therapeutics Inc
PE (TTM)

-0.0017

Very Poor
Price / Book

-0.0346

Very Poor
Price / Sales

0.0059

Excellent
Piotroski F Score

4.0

Indecisive
Market Cap

821028

Enterprise Value

-27569.97 K

ROA (TTM)

-170.31

Very Poor
ROE (TTM)

0

Poor
Net Margin (TTM)

-346.87

Very Poor
Revenue

6.28 %

111118 K
Net Profit

75.80 %

-15951.00 K
Debt to Equity

-0.0101

Very Poor
Altman Z Score

-15.55

Very Poor
Quick Ratio

0.257

Poor
Cash Ratio

0.132

Poor


Highs/Lows of Acorda Therapeutics Inc
PeriodOld priceStock ReturnS&P 500 ReturnsHighLowHigh DateLow Date
One Week1.68 60.65 % 1.54 % 1.62140.611605-Apr-2411-Apr-24
Two Week13.211 95.00 % 3.42 % 13.480.611601-Apr-2411-Apr-24
One Month12.0 94.49 % 5.60 % 14.110.611615-Mar-2411-Apr-24
Three Month16.36 95.96 % 5.95 % 18.00.611618-Jan-2411-Apr-24
Six Months10.7487 93.85 % 17.48 % 18.00.611618-Jan-2411-Apr-24
One year11.0 93.99 % 27.52 % 24.1960.611608-May-2311-Apr-24
Two year33.2 98.01 % 29.70 % 24.80.611631-Oct-2211-Apr-24
Five year1479.6 99.96 % 85.46 % 24.1960.2608-May-2329-Sep-22
Ten year4222.8 99.98 % 182.41 % 272.70.2613-Jan-1529-Sep-22


Technical View of Acorda Therapeutics Inc
RSI

17.04

Bearish
MACD

-3.45

Bearish
ADX

39.16

Bearish
Super Trend

3.91

Mild Bearish
Williams %R

-99.62

Mild Bullish
CCI

-93.05

Mild Bullish


EMA 5

1.46

Mild Bearish
EMA 15

5.21

Strong Bearish
EMA 50

10.21

Strong Bearish
EMA 100

11.80

Strong Bearish
SMA 100

12.78

Whipsaw
SMA 200

13.10

Mild Bearish
SMA 5 / 20

1.02 / 8.15

Strong Bearish
SMA 15 / 50

6.57 / 11.85

Strong Bearish
SMA 50 / 200

11.85 / 13.10

Bearish




Charts of Acorda Therapeutics Inc


Returns of Acorda Therapeutics Inc with Peers
Period / StockACORSBFMNEPTHSTOGLS
1 Week-60.65%4.20%-57.89%5.00%-92.41%
1 Mth-94.49%-75.53%-57.89%-58.00%-94.73%
3 Mth-95.96%-84.78%-61.98%-37.31%-96.62%
6mth-93.85%-96.49%-96.87%-38.24%-98.75%
1 Year-93.99%-98.37%-99.09%-72.73%-99.76%
2 Year-98.01%-99.53%-99.96%-94.57%-99.88%
5 Years-99.96%-93.06%-100.00%-99.88%-
charts-
View All Together in Chart      Inline           Tile

Compare Fundamentals of Acorda Therapeutics Inc with Peers
Ratio / StockACORSBFMNEPTHSTOGLS
PE-0.0017-0.050-0.0112-52.300.0171
P/B-0.03460.0106-0.020563.95-0.163
ROA-170.31-16.13-416.28-83.9178.34
ROE0-20.990-111.370
Debt To Equity-0.01010.0056-1.950-1013.84
Revenue111118 K
6.28 % 		20352.43 K
368.35 % 		52615.34 B
107824570 % 		19000.00
99.50 % 		25767.00 K
130.37 %
Net Income-15951.00 K
75.80 % 		-26768.33 K
0.089 % 		-170880.45 B
241130345 % 		-12377.00 K
11.41 % 		-95062.00 K
1.84 %


Technicals of Acorda Therapeutics Inc with Peers
Technical / StockACORSBFMNEPTHSTOGLS-
ADX39.1622.3722.4131.9715.17
CMF-0.438-0.231-0.5770.291-0.194
MFI0.92578.0179.4849.1133.16
RSI17.0431.7530.8639.2925.91
MACD Abv SignalFalseTrueFalseFalseFalse
Price Above 50 MAFalseFalseFalseFalseFalse-
Price Above 200 MAFalseFalseFalseFalseFalse-


About : Acorda Therapeutics Inc

Address : 2 Blue Hill Plaza, Pearl River, NY, United States, 10965
Tel : 914 347 4300
URL : https://www.acorda.com
Code : ACOR, ISIN : US00484M6012, Exchange : NASDAQ, Country : USA
Fiscal Year End : December
IPO date : 10_Feb_2006
Employee Count : 102

Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, it has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. The company was incorporated in 1995 and is headquartered in Pearl River, New York. On April 1, 2024, Acorda Therapeutics, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.


Note : All Data Generated at the End of Trading Hours (EOD Data)